Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology

Oligonucleotides

Volumn 14, Issue 2, 2004, Pages 130-146

  Jepsen, Jan Stenvang ^a   Sørensen, Mads D ^b   Wengel, Jesper ^c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; LOCKED NUCLEIC ACID; NUCLEIC ACID; RNA; UNCLASSIFIED DRUG;

BINDING AFFINITY; BIOTECHNOLOGY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SPECIFICITY; GENE EXPRESSION; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY;

ANIMALS; BIOTECHNOLOGY; DRUG DESIGN; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H, CALF THYMUS;

EID: 3342961686     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/1545457041526317     Document Type: Review

References (106)

1. AKHTAR, S., HUGHES, M.D., KHAN, A., BIBBY, M., HUSSAIN, M., NAWAZ, Q., DOUBLE, J., and SAYYED, P. (2000). The delivery of antisense therapeutics. Adv. Drug Deliv. Rev. 44, 3-21.
2. ARZUMANOV, A., WALSH, A.P., LIU, X., RAJWANSHI, V.K., WENGEL, J., and GAIT, M.J. (2001a). Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction. Nucleosides Nucleotides Nucleic Acids 20, 471-480.
3. ARZUMANOV, A., WALSH, A.P., RAJWANSHI, V.K., KUMAR, R., WENGEL, J., and GAIT, M.J. (2001b). Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry 40, 14645-14654.
4. BAKER, B.F., and MONIA, B.P. (1999). Novel mechanisms for antisense-mediated regulation of gene expression. Biochim. Biophys. Acta 1489, 3-18.
5. BAUER, S., KIRSCHNING, C.J., HACKER, H., REDECKE, V., HAUSMANN, S., AKIRA, S., WAGNER, H., and LIPFORD, G.B. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA 98, 9237-9242.
6. BENIMETSKAYA, L., MILLER, P., BENIMETSKY, S., MACIASZEK, A., GUGA, P., BEAUCAGE, S.L., WILK, A., GRAJKOWSKI, A., HALPERIN, A.L., and STEIN, C.A. (2001). Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: Relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol. Pharmacol. 60, 1296-1307.
7. BENIMETSKAYA, L., TAKLE, G.B., VILENCHIK, M., LEBEDEVA, I., MILLER, P., and STEIN, C.A. (1998). Cationic porphyrins: Novel delivery vehicles for antisense oligodeoxynucleotides. Nucleic Acids Res. 26, 5310-5317.
8. BONDENSGAARD, K., PETERSEN, M., SINGH, S.K., RAJWANSHI, V.K., KUMAR, R., WENGEL, J., and JACOBSEN, J.P. (2000). Structural studies of LNA:RNA duplexes by NMR: Conformations and implications for RNase H activity. Chem. Eur. J. 6, 2687-2695.
9. BRAASCH, D.A., and COREY, D.R. (2001). Locked nucleic acid (LNA): Fine-tuning the recognition of DNA and RNA. Chem. Biol. 8, 1-7.
10. BRAASCH, D.A., JENSEN, S., LIU, Y., KAUR, K., ARAR, K., WHITE, M.A., and COREY, D.R. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42, 7967-7975.
11. BRAASCH, D.A., LIU, Y., and COREY, D.R. (2002). Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: Effect of mRNA target sequence and chimera design. Nucleic Acids Res. 30, 5160-5167.
12. CHEN, H.X. (2003). Clinical development of antisense oligonucleotides as anti-cancer therapeutics. Methods Mol. Med. 75, 621-636.
13. CHEN, X., and SULLIVAN, P.F. (2003). Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenomics J. 3, 77-96.
14. CHERNOLOVSKAYA, E.L., KOSHKIN, A.A., and VLASSOV, V.V. (2001). Interaction of LNA oligonucleotides with mdr1 promoter. Nucleosides Nucleotides Nucleic Acids 20, 847-850.
15. CHILDS, J.L., DISNEY, M.D., and TURNER, D.H. (2002). Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing. Proc. Natl. Acad. Sci. USA 99, 11091-11096.
16. CHOLEVA, Y., NORHOLM, M., PEDERSEN, S., MOURITZEN, P., HOIBY, P.E., NIELSEN, A.T., MOLLER, S., JAKOBSEN, M.H., and KONGSBAK, L. (2001). Multiplex SNP genotyping using locked nucleic acid and microfluidics. J. Assoc. Lab. Autom. 6, 92-97.
17. CRINELLI, R., BIANCHI, M., GENTILINI, L., and MAGNANI, M. (2002). Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res. 30, 2435-2443.
18. CROOKE, S.T. (2000). Potential roles of antisense technology in cancer chemotherapy. Oncogene 19, 6651-6659.
19. DEMIDOV, V.V. (2003). PNA and LNA throw light on DNA. Trends Biotechnol. 21, 4-7.
20. DOVE, A. (2002). Antisense and sensibility. Nat. Biotechnol. 20, 121-124.
21. DYRSKJOT, L., THYKJAER, T., KRUHOFFER, M., JENSEN, J.L., MARCUSSEN, N., HAMILTON-DUTOIT, S., WOLF, H., and ORNTOFT, T.F. (2003). Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33, 90-96.
22. EDER, P.S., DEVINE, R.J., DAGLE, J.M., and WALDER, J.A. (1991). Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev. 1, 141-151.
23. ELAYADI, A.N., BRAASCH, D.A., and COREY, D.R. (2002). Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 41, 9973-9981.
24. ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TUSCHL, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
25. Exiqon. (2004). www.exiqon.com
26. FLUITER, K., TEN ASBROEK, A.L., DE WISSEL, M.B., JAKOBS, M.E., WISSENBACH, M., OLSSON, H., OLSEN, O., OERUM, H., and BAAS, F. (2003). In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 31, 953-962.
27. FLUITER, K., TEN ASBROEK, A.L., VAN GROENIGEN, M., NOOIJ, M., AALDERS, M.C., and BAAS, F. (2002). Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II. Cancer Res. 62, 2024-2028.
28. FRIEDEN, M., CHRISTENSEN, S.M., MIKKELSEN, N.D., ROSENBOHM, C., THRUE, C.A., WESTERGAARD, M., HANSEN, H.F., ORUM, H., and KOCH, T. (2003). Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res. 31, 6365-6372.
29. GEWIRTZ, A.M., SOKOL, D.L., and RATAJCZAK, M.Z. (1998). Nucleic acid therapeutics: State of the art and future prospects. Blood 92, 712-736.
30. GILES, R.V., RUDDELL, C.J., SPILLER, D.G., GREEN, J.A., and TIDD, D.M. (1995). Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res. 23, 954-961.
31. GILES, R.V., and TIDD, D.M. (1992). Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res. 20, 763-770.
32. GRUNWELLER, A., WYSZKO, E., BIEBER, B., JAHNEL, R., ERDMANN, V.A., and KURRECK, J. (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185-3193.
33. HANSEN, J.B., WESTERGAARD, M., THRUE, C.A., GIWERCMAN, B., and OERUM, H. (2003). Antisense knock-down of PKC-alpha using LNA-oligos. Nucleosides Nucleotides Nucleic Acids 22, 1607-1609.
34. HARTMANN, G., KRUG, A., WALLER-FONTAINE, K., and ENDRES, S. (1996). Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: Dependence on phosphorothioate modification and reversal by heparin. Mol. Med. 2, 429-438.
35. HEMMI, H., TAKEUCHI, O., KAWAI, T., KAISHO, T., SATO, S., SANJO, H., MATSUMOTO, M., HOSHINO, K., WAGNER, H., TAKEDA, K, and AKIRA, S. (2000). A toll-like receptor recognizes bacterial DNA. Nature 408, 740-745.
36. HERTOGHS, K.M., ELLIS, J.H., and CATCHPOLE, I.R. (2003). Use of locked nucleic acid oligonucleotides to add functionality to plasmid DNA. Nucleic Acids Res. 31, 5817-5830.
37. HOEG, A., THRUE, C., OERUM, H., and KRISTJANSEN, P. (2003). In vitro and in vivo efficacy of a HIF-1alpha-antisense oligonucleotide containing locked nucleic acids. Eur. J. Cancer Suppl. 1, s212.
38. IMANISHI, T., and OBIKA, S. (2002). BNAs: Novel nucleic acid analogs with a bridged sugar moiety. Chem. Commun. 16, 1653-1659.
39. JACKSON, A.L., BARTZ, S.R., SCHELTER, J., KOBAYASHI, S.V., BURCHARD, J., MAO, M., LI, B., CAVET, G., and LINSLEY, P.S. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637.
40. JACOBSEN, N., BENTZEN, J., MELDGAARD, M., JAKOBSEN, M.H., FENGER, M., KAUPPINEN, S., and SKOUV, J. (2002a). LNA-enhanced detection of single nucleotide polymorphisms in the apolipoprotein E. Nucleic Acids Res. Methods Online 30 (19), 1 October 2002.
41. JACOBSEN, N., FENGER, M., BENTZEN, J., RASMUSSEN, S.L., JAKOBSEN, M.H., FENSTHOLT, J., and SKOUV, J. (2002b). Genotyping of the apolipoprotein B R3500Q mutation using immobilized locked nucleic acid capture probes. Clin. Chem. 48, 657-660.
42. JACOBSEN, N., NIELSEN, P.S., JEFFARES, D.C., ERIKSEN, J., OHLSSON, H., ARCTANDER, P., and KAUPPINEN, S. (2004) Direct isolation of poly(A)+RNA from 4 M guanidine thiocyanate-lysed cell extracts using locked nucleic acid-oligo(T) capture. Nucleic Acids Res. 32, e64.
43. JANSEN, B., and ZANGEMEISTER-WITTKE, U. (2002). Antisense therapy for cancer - The time of truth. Lancet Oncol. 3, 672-683.
44. JEPSEN, J.S., and WENGEL, J. (2004). LNA-antisense rivals siRNA for gene silencing. Curr. Opin. Drug Discov. Devel. 7, 188-194.
45. (WAF1/CIP1) and estrogen receptor α in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides 14, 147-156.
46. KAUPPINEN, S., NIELSEN, P.S., MOURITZEN, P., NIELSEN, A.T., NORHOLM, M., VISSING, H., KONGSBAK, L., MOLLER, S., and RAMSING, N.B. (2003). The use of LNA microarrays in genomics. PharmaGenomics 3, 24-34.
47. KIRK, B.W., FEINSOD, M., FAVIS, R., KLIMAN, R.M., and BARANY, F. (2002). Single nucleotide polymorphism seeking long-term association with complex disease. Nucleic Acids Res. 30, 3295-3311.
48. KLASA, R.J., GILLUM, A.M., KLEM, R.E., and FRANKEL, S.R. (2002). Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12, 193-213.
49. KOPPELHUS, U., and NIELSEN, P.E. (2003). Cellular delivery of peptide nucleic acid (PNA). Adv. Drug Deliv. Rev. 55, 267-280.
50. KOSHKIN, A.A., FENSTHOLT, J., PFUNDHELLER, H.M., and LOMHOLT, C. (2001). A simplified and efficient route to 2′-O, 4′-C-methylene-linked bicyclic ribonucleosides (locked nucleic acid). J. Org. Chem. 66, 8504-8512.
51. KOSHKIN, A.A., NIELSEN, P., MELDGAARD, M., RAJWANSHI, V.K., SINGH, S.K., and WENGEL, J. (1998a). LNA (locked nucleic acid): An RNA mimic forming exceedingly stable LNA-LNA duplexes. J. Am. Chem. Soc. 120, 13252-13253.
52. KOSHKIN, A.A., RAJWANSHI. V.K., and WENGEL, J. (1998b). Novel convenient syntheses of LNA [2.2.1]bicyclo nucleosides. Tetrahedron Lett. 39, 4381-4384.
53. KOSHKIN, A.A., SINGH, S.K., NIELSEN, P., RAJWANSHI, V.K., KUMAR, R., MELDGAARD, M., OLSEN, C.E., and WENGEL, J. (1998c). LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630.
54. KOZIOLKIEWICZ, M., GENDASZEWSKA, E., MASZEWSKA, M., STEIN, C.A., and STEC, W.J. (2001). The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5′-nucleotidase. Blood 98, 995-1002.
55. KREN, B.T., BANDYOPADHYAY, P., and STEER, C.J. (1998). In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat. Med. 4, 285-290.
56. KRIEG, A.M. (2003). CpG motifs: The active ingredient in bacterial extracts? Nat. Med. 9, 831-835.
57. KRIEG, A.M., YI, A.K., MATSON, S., WALDSCHMIDT, T.J., BISHOP, G.A., TEASDALE, R., KORETZKY, G.A., and KLINMAN, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
58. KURRECK, J. (2003). Antisense technologies. Eur. J. Biochem. 270, 1628-1644.
59. KURRECK, J., WYSZKO, E., GILLEN, C., and ERDMANN, V.A. (2002). Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911-1918.
60. LARROUY, B., BLONSKI, C., BOIZIAU, C., STUER, M., MOREAU, S., SHIRE, D., and TOULME, J.J. (1992). RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: Use of backbone modification to improve specificity. Gene 121, 189-194.
61. LATORRA, D., CAMPBELL, K., WOLTER, A., and HURLEY, J.M. (2003a). Enhanced allele-specific PCR discrimination in SNP genotyping using 3′ locked nucleic acid (LNA) primers. Hum. Mutat. 22, 79-85.
62. LATORRA, D., HOPKINS, D., CAMPBELL, K., and HURLEY, J.M. (2003b). Multiplex allele-specific PCR with optimized locked nucleic acid primers. Biotechniques 34(6), 1150-1152, 1154, 1158.
63. LEBEDEVA, I., BENIMETSKAYA, L., STEIN, C.A., and VILENCHIK, M. (2000). Cellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm. 50, 101-119.
64. LEVIN, A.A. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
65. MARWICK, C. (1998). First "antisense" drug will treat CMV retinitis. JAMA 280, 871.
66. MONIA, B.P., LESNIK, E.A., GONZALEZ, C., LIMA, W.F., McGEE, D., GUINOSSO, C.J., KAWASAKI, A.M., COOK, P.D., and FREIER, S.M. (1993). Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522.
67. MONTEITH, D.K., HENRY, S.P., HOWARD, R.B., FLOURNOY, S., LEVIN, A.A., BENNETT, C.F., and CROOKE, S.T. (1997). Immune stimulation-A class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des. 12, 421-432.
68. MORITA, K., YAMATE, K., KURAKATA, S., ABE, K., IMANISHI, T., and KOIZUMI, M. (2002). Down-regulation of VEGF mRNA expression by 2′-O,4′-C- ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression. Nucleic Acids Res. 2, Suppl. 99-100.
69. MOURITZEN, P., NIELSEN, A.T., PFUNDHELLER, H.M., CHOLEVA, Y., KONGSBAK, L., and MOLLER, S. (2003). Single nucleotide polymorphism genotyping using locked nucleic acid (LNA). Expert Rev. Mol. Diagn. 3, 27-38.
70. NIELSEN, C.B., SINGH, S.K., WENGEL, J., and JACOBSEN, J.P. (1999). The solution structure of a locked nucleic acid (LNA) hybridized to DNA. J. Biomol. Struct. Dynam. 17, 175-191.
71. OBIKA, S., HARI, Y., SUGIMOTO, T., SEKIGUCHI, M., and IMANISHI, T. (2000). Triplex-forming enhancement with high sequence selectivity by single 2′-O,4′-C-methylene bridged nucleic acid (2′,4′-BNA) modification. Tetrahedron Lett. 41, 8923-8927.
72. OBIKA, S., HEMAMAYI, R., MASUDA, T., SUGIMOTO, T., NAKAGAWA, S., MAYUMI, T., and IMANISHI, T. (2001a). Inhibition of ICAM-1 gene expression by antisense 2′,4′-BNA oligonucleotides. Nucleic Acids Res. 1, (Suppl), 145-146.
73. OBIKA, S., NANBU, D., HARI, Y., ANDOH, J., MORIO, K., DOI, T., and IMANISHI, T. (1998). Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Lett. 39, 5401-5404.
74. OBIKA, S., NANBU, D., HARI, Y., MORIO, K., IN, Y., ISHIDA, T., and IMANISHI, T. (1997). Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett. 38, 8735-8738.
75. OBIKA, S., UNEDA, T., SUGIMOTO, T., NANBU, D., MINAMI, T., DOI, T., and IMANISHI, T. (2001b). 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): Synthesis and triplex-forming properties. Bioorg. Med. Chem. 9, 1001-1011.
76. OPALINSKA, J.B., and GEWIRTZ, A.M. (2002). Nucleic-acid therapeutics: Basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503-514.
77. ORUM, H., JAKOBSEN, M.H., KOCH, T., VUUST, J., and BORRE, M.B. (1999). Detection of the factor V Leiden mutation by direct allele-specific hybridization of PCR amplicons to photoimmobilized locked nucleic acids. Clin. Chem. 45, 1898-1905.
78. PAREKH-OLMEDO, H., DRURY, M., and KMIEC, E.B. (2002). Targeted nucleotide exchange in Saccharomyces cerevisiae directed by short oligonucleotides containing locked nucleic acids. Chem. Biol. 9, 1073-1084.
79. PETERSEN, M., BONDENSGAARD, K., WENGEL, J., and JACOBSEN, J.P. (2002). Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids. J. Am. Chem. Soc. 124, 5974-5982.
80. PETERSEN, M., and WENGEL, J. (2003). LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol. 21, 74-81.
81. PICHON, C., MONSIGNY, M., and ROCHE, A.C. (1999). Intracellular localization of oligonucleotides: Influence of fixative protocols. Antisense Nucleic Acid Drug Dev. 9, 89-93.
82. PIROLLO, K.F., RAIT, A., SLEER, L.S., and CHANG, E.H. (2003). Antisense therapeutics: From theory to clinical practice. Pharmacol. Ther. 99, 55-77.
83. SCHUBERT, S., GUL, D.C., GRUNERT, H.P., ZEICHHARDT, H., ERDMANN, V.A., and KURRECK, J. (2003). RNA cleaving "10-23" DNAzymes with enhanced stability and activity. Nucleic Acids Res. 31, 5982-5992.
84. SILAHTAROGLU, A.N., TOMMERUP, N., and VISSING, H. (2003). FISHing with locked nucleic acids (LNA): Evaluation of different LNA/DNA mixmers. Mol. Cell Probes 17, 165-169.
85. SIMEONOV, A., and NIKIFOROV, T.T. (2002). Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection. Nucleic Acids Res. 30(1), 1 September 2002.
86. SINGH, S.K., NIELSEN, P., KOSHKIN, A.A., and WENGEL, J. (1998). LNA (locked nucleic acids): Synthesis and high-affinity nucleic acid recognition. Chem. Commun. 455-456.
87. SINGH, S.K., and WENGEL, J. (1998). Universality of LNA-mediated high-affinity nucleic acid recognition. Chem. Commun. 1247-1248.
88. SORENSEN, M.D., KVAERNO, L., BRYLD, T., HAKANSSON, A.E., VERBEURE, B., GAUBERT, G., HERDEWIJN, P., and WENGEL, J. (2002). Alpha-L-ribo-configured locked nucleic acid (alpha-L-LNA): Synthesis and properties. J. Am. Chem. Soc. 124, 2164-2176.
89. STEIN, C.A. (1999). Two problems in antisense biotechnology: In vitro delivery and the design of antisense experiments. Biochim. Biophys. Acta 1489, 45-52.
90. STEIN, C.A. (2000). Is irrelevant cleavage the price of antisense efficacy? Pharmacol. Ther. 85, 231-236.
91. STEIN, C.A., TONKINSON, J.L., ZHANG, L.M., YAKUBOV, L., GERVASONI, J., TAUB, R., and ROTENBERG, S.A. (1993). Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32, 4855-4861.
92. STEIN, H., and HAUSEN, P. (1969). Enzyme from calf thymus degrading the RNA moiety of DNA-RNA hybrids: Effect on DNA-dependent RNA polymerase. Science 166, 393-395.
93. SUMMERTON, J. (1999). Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489, 141-158.
94. TOLSTRUP, N., NIELSEN, P.S., KOLBERG, J.G., FRANKEL, A.M., VISSING, H., and KAUPPINEN, S. (2003). OligoDesign: Optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling. Nucleic Acids Res. 31, 3758-3762.
95. TORTORA, G., and CIARDIELLO, F. (2003). Antisense strategies targeting protein kinase C: Preclinical and clinical development. Semin. Oncol. 30, 26-31.
96. VAN DE VIJVER, M.J., HE, Y.D., VAN'T VEER, L.J., DAI, H., HART, A.A., VOSKUIL, D.W., SCHREIBER, G.J., PETERSE, J.L., ROBERTS, C., MARTON, M.J., PARRISH, M., ATSMA, D., WITTEVEEN, A., GLAS, A., DELAHAYE, L., VAN DER VELDE, T., V, BARTELINK, H., RODENHUIS, S., RUTGERS, E.., FRIEND, S.H., and BERNARDS, R. (2002). A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009.
97. VAN'T VEER, L.J., DAI, H., VAN DE VIJVER, M.J., HE, Y.D., HART, A.A., MAO, M., PETERSE, H.L., VAN DER KOOY, K., MARTON, M.J., WITTEVEEN, A.T., SCHREIBER, G.J., KERKHOVEN, R.M., ROBERTS, C., LINSLEY, P.S., BERNARDS, R., and FRIEND, S.H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
98. VESTER, B., LUNDBERG, L.B., SORENSEN, M.D., BABU, B.R., DOUTHWAITE, S., and WENGEL, J. (2002). LNAzymes: Incorporation of LNA-type monomers into DNAzymes markedly increases RNA cleavage. J. Am. Chem. Soc. 124, 13682-13683.
99. VICKERS, T.A., KOO, S., BENNETT, C.F., CROOKE, S.T., DEAN, N.M., and BAKER, B.F. (2003). Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278, 7108-7118.
100. VOLLMER, J., JANOSCH, A., LAUCHT, M., BALLAS, Z.K., SCHETTER, C., and KRIEG, A.M. (2002). Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 12, 165-175.
101. VOLLMER, J., JEPSEN, J.S., UHLMANN, E., SCHETTER, C., JURK, M., WADER, T., WÜLLNER, M., and KRIEG, A.M. (2004). Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides 14, 23-31.
102. WAHLESTEDT, C., SALMI, P., GOOD, L., KELA, J., JOHNSSON, T., HOKFELT, T., BROBERGER, C., PORRECA, F., LAI, J., REN, K., OSSIPOV, M., KOSHKIN, A., JAK[INF]OBS[INF]EN, N., SKOUV, J., OERUM, H., JACOBSEN, M.H., and WENGEL, J. (2000). Potent and non-toxic antisense Oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA 97, 5633-5638.
103. WENGEL, J. (1999). Synthesis of 3′-C- and 4′-C-branched Oligonucleotides and the development of locked nucleic acid (LNA). Ace. Chem. Res. 32, 301-310.
104. WENGEL, J., VESTER, B., LUNDBERG, L.B., DOUTHWAITE, S., SORENSEN, M.D., BABU, B.R., GAIT, M.J., ARZUMANOV, A., PETERSEN, M., and NIELSEN, J.T. (2003). LNA and alpha-L-LNA: Towards therapeutic applications. Nucleosides Nucleotides Nucleic Acids 22, 601-604.
105. WU, H., LIMA, W.F., and CROOKE, S.T. (1999). Properties of cloned and expressed human RNase H1. J. Biol. Chem. 274, 28270-28278.
106. ZAMARATSKI, E., PRADEEPKUMAR, P.I., and CHATTOPADHYAYA, J. (2001). A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J. Biochem. Biophys. Methods 48, 189-208.